Risk-based Environmental Monitoring - PQRI
Risk-Based Environmental Monitoring Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI
Presenter Marsha Stabler Hardiman Over 20 years experience in the Pharmaceutical and Medical Device industries Microbiologist/EM Expert Senior Consultant, Concordia ValSource LLC
Quality By Design for Sterile Product Manufacturing – Risk Based EM Environmental Monitoring (EM) is Evolving Not the same EM Programs of the past Sterile Manufacturing Critical Quality Attribute (CQA) Absence of biological contamination EM is a detection tool to help us achieve this CQA Novel Approach to Environmental Monitoring Value added and Risk Based EM Programs cGMP expectation
Presentation Outline Definitions Environmental Monitoring (EM) Regulations Room Classifications -EM Program Misconceptions Risk-based EM Risk Assessment Tool Media Equipment Incubation and Data Collection Microbial IDs
What is Environmental Monitoring? Sampling of controlled environments for non-viable and viable air particulates as well as surface viables Allows for assessment of effectiveness of cleaning/disinfection Allows for identification of trends Facilitate early detection of potential problems
What is Risk Based EM? Application of QRM tools and approaches into your EM Program design and throughout the product lifecycle Understanding your products and processes Understanding your microbial contamination risks Ensuring that proper risk mitigations are in place to help prevent contaminations Ensuring that EM sample sites selection and sampling frequencies reflect this understanding and are properly established to best detect potential contamination You are the expert in your products and processes – your EM Program should reflect this knowledge
Regulations/Guidance ISO 14644-1 “Cleanrooms and Associated Controlled Environments - Part 1: Classification of Air Cleanliness”, 1999 USP 1116 “Microbiological Control and Monitoring of Aseptic Processing Environments” USP 1115 “ Bioburden Control of Nonsterile Drug Substances and Products” FDA Aseptic Processing Guideline EU Annex 1 Japan Aseptic Processing Guide and JP AAMI TIR 52 – Environmental Monitoring for the Manufacture of Terminally Sterilized Healthcare Products – Medical Device
Design and Construction of Cleanrooms Room Classification ISO 14644 assigns ISO classification levels to be used for the specification of air cleanliness in cleanrooms and associated controlled environments Healthcare ISO 5 -8 Classification – defined per ISO 14644-1 level (or the process of specifying or determining the level) of airborne particulate cleanliness applicable to a cleanroom or clean zone, expressed in terms of an ISO Class N, which represents maximum allowable concentrations (in particles per cubic meter of air) for considered sizes of particles
Airborne Particulate Cleanliness Classes ISO 14644-1 maximum allowable particle concentrations Airborne particulate cleanliness shall be designated by a classification number ISO Class 0.5 µm 5.0 µm ISO 5 3,520 29 ISO 6 35,200 293 ISO 7 352,000 2,930 ISO 8 3,520,000 29,300 Maximum concentration limits (particles 0.5 or 5 um/m3 of air)
Definitions of Room Occupancy States as-built condition where the installation is complete with all services connected and functioning but with no production equipment, materials, or personnel present at-rest condition where the installation is complete with equipment installed and operating in a manner agreed upon by the customer and supplier, but with no personnel present operational condition where the installation is functioning in the specified manner, with the specified number of personnel present and working in the manner agreed upon The particulate cleanliness of air in a cleanroom shall be defined in one or more occupancy states and the considered particle size shall be stated
Common Misperception with ISO 14644 B 4.1.1 - Minimum number of sample point locations based on formula: NL A (NL (square root) of A) NL is the minimum number of sampling locations (rounded up to a whole number) A is the area of the cleanroom or clean zone in square meters. Room grid based on room area Specific to nonviable particulate sample locations for cleanroom classification – evaluates air quality against design – not routine EM
Establishment of Qualification Study EM Sampling Plan and Sites ISO 14644 grid approach for room classification During initial startup, locations for air and surface monitoring determined Locations should include those in close proximity to exposed product, product contact surfaces Prospective risk analysis shall be performed to develop a rationale for the sampling locations and frequencies Not all rooms of the same ISO Class need the same control levels Avoid over sampling as well as under sampling – focus on reduction of contamination sources Walls and Floors
USP 1116 Microbiological Control and Monitoring of Aseptic Processing Environments Significant changes made to USP 1116 in late 2012 This Chapter is NOW specific to EM of aseptic processing environments Sterile products, bulk “sterile” drug substances, sterile intermediates, excipients, medical devices (i.e., contact lens solutions) Risk based sample locations and frequencies with documented rationale Table 2 suggests sampling frequency aseptic processing areas Rate of occurrence of excursions in place of CFU levels Contamination Recovery Rates – percentage of plates showing any microbial recovery regardless of the number of CFU for each cleanroom (Table 3) Action levels should be based on empirical process capability If exceed, Table 3 or process capability levels, take corrective action ISO 5 excursions 15 CFU single sample, significant excursion
USP 1115 Bioburden Control of Nonsterile Drug Substances and Products Describes Microbial Assessment of Non-sterile Product Manufacturing Environments Part of Risk-Based Microbiological Control Program Contamination Recovery Rates from 1116 are not intended for nonsterile environments Contamination likely depends on level of human activity and levels of gowning Sampling locations should be selected based on risk evaluation Frequency of monitoring should reflect the potential risk associated with the dosage form Products that are resistant to microbial contamination require little to no monitoring
EM Program’s of the Past Viable and Non-Viable Center of the Room Surface Viable Center of Each Wall Floor - corner of each room, center of room IS THIS WRONG? IS THIS RISK BASED?
EM Program Risk-based Approach Two way approach – similar but different based on prior knowledge: 1 – New EM Program 2 – Reassessment of Current/Existing EM Program
New EM Program New Facility? New Controlled Environment additions to existing facility? Any Prior Knowledge contamination types and levels? Prior knowledge is an input Assess Microbial Risk of New Area Product Type Process
Step 1 - Planning Risk Management Planning Determine Team/Members – cross functional (Micro, QA, MFGing, Facilities, Engineering) Select Facilitator – not bias to activity Define Scope of Risk Activities for EM Program assessment Determine the Risk Management Tools to be used Determine Scoring to be used – company procedure may already exist Determine Communication of Risk Plan Who needs to be communicated to, when, how often, how much detail Impact to Regulatory Filings Costs
Step 2 - Assess Activity Affecting Microbial State of Control Brainstorm Fishbone Cross functional team – Microbiologists, Manufacturing, Engineers, Quality, Facilities May want to break down by sub-teams for different rooms if large facility No need to discuss current controls in place at this point Simply identifying all areas of microbial risk
CAUSES OF MICROBIAL CONTAMINATION MAN (HUMAN) MACHINE MOTHER NATURE EQ 1 Behavior Power Outages EQ 2 Gowning HVAC Fires Utilities Training Awareness Sinks Floods Airlocks Washers Raw Materials Batch Records MICROBIAL CONTROL Cleaning Cleaning Agents/Supplies Charging Vessel Hoses Carts/Cart Wheels Gowning Materials Tablet Coating Raw Material Weighing/Dispensing MATERIALS METHODS
Step 3 - Assess Activity and Flow Gemba (go see) walk each room/area if possible If construction phase, do via paper until you can get in the area Best case - Work with engineers prior to design and construction start to identify microbial risk points and plan them OUT Assess planned personnel flow Assess planned material flow Sample site locations should be based on risk of activity Likelihood of contamination from process Open or Closed Process People likely largest contributors of room contamination if closed process Maybe you have a wet process – Gram negatives Contamination from other products
Step 4 – Perform Risk Assessment Next use the information obtained in the brainstorming activity and floor assessment as a foundation to perform a risk assessment Include known controls and risk mitigations Cross functional team – Microbiologists, Manufacturing, Engineers, Quality, Facilities Preliminary Hazard Analysis (PHA) or Failure Modes and Effects Analysis (FMEA)
FMEA Process Example Identify Hazards Example: Not meeting Air Quality Viable EM Levels Identify Harms Example: Airborne contamination in controlled environment Identify Hazardous Conditions Contamination of Room EQ Contamination of product contact surfaces Contamination of People Contamination of work surfaces Determine Severity, Occurrence and Detection Scores Determine Risk Priority Number (RPN) Determine Control Measures in Place Example: Cleaning/Disinfection Example: HVAC System Determine if Additional Controls are Needed Example: More Gowning
Risk Ranking Determine HIGH, MEDIUM and LOW risk areas from RPN results Could be used to determine frequency or site locations HIGH – daily MEDIUM – weekly LOW – monthly
Step 5 - Selection of Sample Locations and Sampling Frequencies Use all prior tools to now select your sample sites Document your rationale based on the risk of contamination Same sized (area) and same class rooms may have different numbers of required sample sites based on risk of contamination in each room Make it about the activity, flow and VALUE ADDED UNDERSTAND THE PROCESS IN EACH ROOM and the MICROBIAL RISK POINTS Ability to assess effectiveness of sanitization – for that reason floor and wall locations may still be needed in your program – reduced number and justification/thought process
Reassessment of Current EM Program Years of DATA which is KNOWLEDGE which you will use to make changes to your existing EM Program Sample site locations Frequency Type of media Incubation
Step 1 - Planning Risk Management Planning Determine Team/Members – cross functional (Micro, QA, MFGing, Facilities, Engineering) Select Facilitator – not bias to activity Define Scope of Risk Activities for EM Program assessment Determine the Risk Management Tools to be used Determine Scoring to be used – company procedure may already exist Determine Communication of Risk Plan Who needs to be communicated to, when, how often, how much detail Impact to Regulatory Filings Cost Impact
Step 2 – Previous Risk Assessment Review Do you have a Product and/or Process Risk Assessment which already identifies the microbial contamination risk points in your processes? HOPEFULLY – YES If No – This is your step 2, Q8/Q9/Q10 or ISO 14197 Cross-functional activity Fishbone from New EM Program Slides Assume Yes Perform a review of this document to identify your microbial risk points as a starting place
Step 3 – Data Review Current EM Assess current EM locations and results What are your trouble spots – frequent alerts/actions or recovery of objectionable organisms Flag these – likely keeper for your new EM Program
Step 4 – Floor Walk/Gemba Assess EQ, material and people flow ON THE FLOOR Talk to current Production Operators Ask them what they see as microbial risk points They have VAST knowledge from being on the floor everyday Cross functional – smaller group than risk assessment Microbiology Lead MFGing support Most process knowledge Where have you had bioburden or water or compressed air contamination concerns?
Step 5 – Select New Sample Locations and Sampling Frequencies Document all findings and risk points You can perform a modified risk assessment – using knowledge gained in product and process risk assessments Talk about activity, people and flow in each room Rationalize new chosen sample locations based on microbial contamination risks in these areas Documentation needs to be a living document, signed off Site Head, QA Head, Microbiology Management at a minimum.
Example of Modified Risk Assessment Room Number Room Description Classification Current Number V/NV/S locations Microbial Risks in Rooms People Movements/Flow Number Proposed New V/NV/S locations Comments discussing rationale based on risk
Documentation Initial Microbial Risk Findings – Fishbone Formal Risk Assessment – PHA or FMEA Or review of Prior Modified Risk Assessment Suggest Prepare Report – describe rationale and shows your thought process Sign Off, Retain, Revisit
Execute Protocol If new sample locations and frequency are very different than your prior EM Program, suggest execution of protocol to collect baseline data Aid in setting alert/action levels
SOP Changes – Change Control Once new locations are selected, documented, agreed upon Revise all current SOPS/maps EM Software Program – changes/cost Regulatory Filing Impact Considerations
Training Microbiology Staff New SOPs New Locations New Equipment New Sample Volumes New Sample Frequencies New Media MENTORING on WHY STRESS UNDERSTANDING THE PROCESS
Rapid Methods Real time particle monitoring -Biological fluorescence Continuous monitoring
Media Types Media used should be evaluated for suitability of the intended purpose TSA – Soybean-casein Digest Agar SDA –Sabouraud Dextrose Agar Lower pH 5.6 inhibits bacterial growth – favors growth of fungi Chemicals that counteract the effect of antimicrobials P80 and Lecithin D/E Neutralizer
Incubation Temperatures 20 – 25C 30 – 35C Start high, read, go low, read – 7 days TSA 30-35C SDA 20-25C Have data to support what you are using for incubation times and temperatures
Microbial Identifications Which ones do I need to ID? Gram stain only? Genus and species? Genetic ID Based on risk FDA Aseptic Processing Guidance – “genotypic methods have been shown to be more accurate and precise than traditional biochemical and phenotypic techniques”-especially valuable for investigations into failures (sterility test, media fill contamination)
Thank You FDA/PQRI and Attendees Marsha Stabler Hardiman ConcordiaValsource LLC mstabler@concordiavalsource.com 949-412-6683
USP 1116 Microbiological Control and Monitoring of Aseptic Processing Environments Significant changes made to USP 1116 in late 2012 This Chapter is NOW specific to EM of aseptic processing environments Sterile products, bulk "sterile" drug substances, sterile intermediates, excipients,
Sep 09, 2010 · PQRI Portal Overview The PQRI Portal is the entry page used by PQRI and PRU participants to access services. It is a method for ensuring secure access to protected information to authenticated users. The PQRI Portal has expanded to accept new user
Reporting Initiative (PQRI). Each measure is assigned a unique number. Measure numbers for 2009 PQRI represent a continuation in numbering from the 2008 PQRI measures 1 through 134. Gaps in measure . 130 . 54 . 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain . C, R . 133 . 55 . 12-Lead Electrocardiogram (ECG) Performed .
Nov 06, 2003 · process powder mixing, the FDA published a draft guidance for industry on blend uniformity analysis in August 1999.2 Comments submitted to the docket resulted in the formation of the Blend Uniformity Working Group (BUWG) by the Product Quality Research Institute (PQRI).3 The PQRI BUWG conducted a pu
PQRI MEASURE ICD-9 CODES CODE & WHEN MODIFIERS 139: Cataract: Pre-Op Assess Comprehensive Preoperative 66982, 66983 66984 0014F Date of surgery 8P: Unspecified 140: AMD: AREDS Recommend AREDS Vitamins 362.50, 362.51 362.52 4177F Date of exam 8P: Unspecified 141: POAG: IOP 15% IOP by 15% or have Plan 365.10, 365.11
Pharmaceutical Product Development: Evolving Regulatory Landscape. 4th PQRI/FDA Conference on Advancing Product Quality, April 9-11, 2019. 2 2002: Pharmaceutical cGMPsfor the 21st Century. 2006: . Introducing FDA'S New Initiative: KASA (Knowledge-aided Assessment and Structured Application) - Moderator: Lawrence Yu
Risk Matrix 15 Risk Assessment Feature 32 Customize the Risk Matrix 34 Chapter 5: Reference 43 General Reference 44 Family Field Descriptions 60 ii Risk Matrix. Chapter 1: Overview1. Overview of the Risk Matrix Module2. Chapter 2: Risk and Risk Assessment3. About Risk and Risk Assessment4. Specify Risk Values to Determine an Overall Risk Rank5
telemetry 1.24 Service P threshold_migrator 2.11 Monitoring P tomcat 1.30 Monitoring P trellis 20.30 Service P udm_manager 20.30 Service P url_response 4.52 Monitoring P usage_metering 9.28 Monitoring vCloud 2.04 Monitoring P vmax 1.44 Monitoring P vmware 7.15 Monitoring P vnxe_monitor 1.03 Monitoring vplex 1.01 Monitoring P wasp 20.30 UMP P .
Accounting involves recording business transactions and, this in turn, leads to the generation of financial information which can be used as the basis of good financial control and planning. Inadequate record keeping and a lack of effective planning ultimately lead to poor financial results. It is vital that owners and managers of businesses recognise the indications of potential difficulties .
